Frankfurt - Delayed Quote EUR

Orion Oyj (OFK.F)

45.07

+0.21

+(0.47%)

At close: January 10 at 9:48:47 PM GMT+1

Orion’s collaboration partner Bayer submits application in China for third indication of darolutamide

ORION CORPORATION INVESTOR NEWS 7 JANUARY 2025 at 9:00 EET Orion’s collaboration partner Bayer submits application in China for third indication of darolutamide Orion’s collaboration partner Bayer has submitted an application to the Center of Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) for the oral androgen receptor inhibitor (ARi) darolutamide. Bayer is seeking approval for the use of darolutamide in combination with androgen deprivation therapy (ADT) in pat

GlobeNewswire 5 days ago

ORINF

ORINY
3 Leading Dividend Stocks Yielding Up To 8.5%

As global markets navigate a mixed landscape of fluctuating consumer confidence and economic indicators, investors are increasingly drawn to the stability offered by dividend stocks. In times of uncertainty, these stocks can provide a reliable income stream, making them an attractive option for those seeking to balance growth with income in their investment portfolios.

Simply Wall St. 9 days ago

SUEZF

SUEZY

AEMMF
Orion and Marinus terminate agreement for ganaxolone in Europe

ORION CORPORATION PRESS RELEASE 30 DECEMBER 2024 at 14.00 EET Orion and Marinus terminate agreement for ganaxolone in Europe Orion Corporation (“Orion”) and Marinus Pharmaceuticals, Inc. (“Marinus”) have decided to mutually terminate their European wide marketing and distribution agreement for ganaxolone. Marinus regains ganaxolone’s commercial rights in Europe where the compound is approved for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5)

GlobeNewswire 12 days ago

ORINF

ORINY
CORRECTION: Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel

Mikko Kemppainen Photo of Mikko Kemppainen ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES BOARD/MANAGEMENT/AUDITORS 19 DECEMBER 2024 at 22.45 EET CORRECTION: Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel Orion corrects the stock exchange release published on 19 December at 19.00 EET. In the original English stock exchange release the first quote by CEO Liisa Hurme differs from the first quote in the Finnish stock exchange rele

GlobeNewswire 23 days ago

ORINF

ORINY
Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel

Mikko Kemppainen Photo of Mikko Kemppainen ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES BOARD/MANAGEMENT/AUDITORS19 DECEMBER 2024 at 19.00 EET Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel Olli Huotari, Senior Vice President responsible for Corporate Functions organization of the Orion Group and Secretary to the Board of Directors of Orion Corporation, and a member of the Executive Management Board of the Orion Group informe

GlobeNewswire 23 days ago

ORINF

ORINY
Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics

ORION CORPORATION PRESS RELEASE 18 DECEMBER 2024 at 17.00 EET Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics Orion Corporation (“Orion”) and Abilita Therapeutics (“Abilita”) announced today that they have entered into a research collaboration and option to license agreement to develop innovative antibody therapeutics in the areas of oncology and pain. Under the terms of the agreement, Orion gains access t

GlobeNewswire 24 days ago

ORINF

ORINY
Penalty payment to a member of Orion’s Board of Directors for delay in notifying managers’ transaction

ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE12 DECEMBER 2024 at 20.30 EET Penalty payment to a member of Orion’s Board of Directors for delay in notifying managers’ transaction In accordance with the applicable regulations, Orion Corporation discloses the following information: The Financial Supervisory Authority (FIN-FSA) has imposed a penalty payment of EUR 6,000 on Ari Lehtoranta, a member of the Board of Directors of Orion, bec

GlobeNewswire 30 days ago

ORINF

ORINY
142,701 Orion Corporation A shares converted into B shares

ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE27 NOVEMBER 2024 at 9.00 EET 142,701 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 142,701 A shares have been converted into 142,701 B shares. The conversion has been entered into the Trade Register on 27 November 2024. The total number of shares in Orion Corporation is 141,134,278 which, after the conv

GlobeNewswire last month

ORINF

ORINY
3 Prominent Dividend Stocks For November 2024

As global markets navigate a landscape marked by strong labor market data and geopolitical tensions, U.S. stock indexes have approached record highs with broad-based gains, fueled by positive sentiment from declining jobless claims and steady home sales. In this environment of economic optimism and cautious anticipation of Federal Reserve policy decisions, dividend stocks stand out as an attractive option for investors seeking stability and income. A good dividend stock typically combines a...

Simply Wall St. last month

ORINF

ORINY
Orion Research Foundation grants EUR 1,109,000 for research in 2025

Orion Research Foundation grants EUR 1,109,000 for research in 2025 Press release 22 November, 2024 at 9.00 EET Orion Research Foundation sr is distributing EUR 1,109,000 in research grants based on applications for 2025. Orion Research Foundation awards grants of max EUR 50,000 for 19 researchers for postdoctoral research and max EUR 6,000 for 93 young researchers for doctoral dissertation work. Orion Research Foundation sr is annually distributing its return on investment and donations from Or

GlobeNewswire last month

ORINF

ORINY
Orion and Alligator Bioscience amend their agreement concerning two bispecific antibodies

ORION CORPORATION INVESTOR NEWS 19 NOVEMBER 2024 at 18.30 EET Orion and Alligator Bioscience amend their agreement concerning two bispecific antibodies Orion Corporation and Alligator Bioscience AB have agreed on the conversion of the previously granted royalty-bearing license to Orion Corporation to two bispecific antibodies that the companies have been successfully developing in collaboration using Alligator’s RUBY® bispecific format to a perpetual, fully paid, royalty-free license. Orion will

GlobeNewswire last month

ORINF

ORINY
Orion Corporation: Managers’ transactions – Henrik Stenqvist

ORION CORPORATION MANAGERS’ TRANSACTIONS 1 NOVEMBER 2024 at 9.45 EET Orion Corporation: Managers’ transactions – Henrik Stenqvist Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Hen

GlobeNewswire 2 months ago

ORINF

ORINY
Orion Group Interim Report January–September 2024

ORION CORPORATION INTERIM REPORT 1–9/2024 29 OCTOBER 2024 at 12:00 EET Orion Group Interim Report January–September 2024 Net sales totalled EUR 1,108.0 (January–September 2023: 868.5) million Operating profit was EUR 323.8 (182.0) millionBasic earnings per share were EUR 1.83 (1.01)Cash flow from operating activities per share was EUR 1.46 (0.50)The outlook for 2024 was upgraded during the reporting period on 11 September 2024: Net sales are estimated to be EUR 1,470 million to EUR 1,510 million

GlobeNewswire 2 months ago

ORINF

ORINY
Inside information: Orion terminates ODM-111 development program due to narrow therapeutic window of the molecule

ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION24 OCTOBER 2024 at 19.50 EEST Inside information: Orion terminates ODM-111 development program due to narrow therapeutic window of the molecule Orion Corporation has decided to terminate the ODM-111 development program based on the risk-benefit analysis on the results of a longer non-clinical toxicology study. Recent findings indicate that the profile of the ODM-111 molecule does not support long-term use of ODM-111 and progression to

GlobeNewswire 2 months ago

ORINF

ORINY
Orion publishes Interim Report for January–September 2024 and holds a webcast on 29 October 2024

ORION CORPORATION PRESS RELEASE 15 OCTOBER 2024 at 9.00 EEST Orion publishes Interim Report for January–September 2024 and holds a webcast on 29 October 2024 Orion will publish Interim Report for January–September 2024 on Tuesday, 29 October 2024 at approximately 12.00 noon EET. The release and related presentation material will be available on the company’s website at www.orion.fi/en/investors after publishing. Webcast and conference call A webcast and a conference call for analysts, investors

GlobeNewswire 2 months ago

ORINF

ORINY
Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU

ORION CORPORATION INVESTOR NEWS 14 OCTOBER 2024 at 11.00 EEST Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU Orion’s collaboration partner Bayer today announced the submission of an application to the European Medicines Agency (EMA) for the oral androgen receptor inhibitor (ARi) darolutamide. Bayer is seeking approval for the use of darolutamide in combination with androgen deprivation therapy (ADT) in patients with metastatic hormone-sensi

GlobeNewswire 2 months ago

ORINF

ORINY
Orion’s near-term climate targets approved by the Science Based Targets initiative

ORION CORPORATIONPRESS RELEASE30 SEPTEMBER 2024 at 10.00 a.m. EEST Orion’s near-term climate targets approved by the Science Based Targets initiative Orion Corporation is proud to announce that the Science Based Targets initiative (SBTi) has validated our near-term science-based targets. This means that our greenhouse gas (GHG) emissions reduction targets align with the latest climate science to limit global warming to 1.5°C above pre-industrial levels. Orion Corporation commits to reduce absolu

GlobeNewswire 3 months ago

ORINF

ORINY
Orion OYJ (ORINY) Is a Great Choice for 'Trend' Investors, Here's Why

Orion OYJ (ORINY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Zacks 3 months ago

ORINF

ORINY
Orion’s collaboration partner Bayer submits application to U.S. FDA for third indication of darolutamide which has become the first ever Orion-originated blockbuster

ORION CORPORATION INVESTOR NEWS 26 SEPTEMBER 2024 at 11.00 EEST Orion’s collaboration partner Bayer submits application to U.S. FDA for third indication of darolutamide which has become the first ever Orion-originated blockbuster Orion’s collaboration partner Bayer today announced the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for the oral androgen receptor inhibitor (ARi) darolutamide. Bayer is seeking approval for the use of daroluta

GlobeNewswire 3 months ago

ORINF

ORINY
Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation Collaboration in Oncology

ORION CORPORATION PRESS RELEASE 25 SEPTEMBER 2024 at 15.00 EEST Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation Collaboration in Oncology Orion Corporation and Aitia, an AI-enabled biotechnology company and the leader in the development and application of Causal AI and "Digital Twins" to discover and develop new drugs, announced today that the companies have entered into agreement to create new Gemini Digital Twins to help in the fight against cancer. Cancer is a critical glob

GlobeNewswire 3 months ago

ORINF

ORINY

Performance Overview

Return	OFK.F	OMX Helsinki_PI
YTD	+4.91%	0.00%
1-Year	+12.21%	0.00%
3-Year	+42.25%	0.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Orion Oyj (OFK.F)

Orion’s collaboration partner Bayer submits application in China for third indication of darolutamide

3 Leading Dividend Stocks Yielding Up To 8.5%

Orion and Marinus terminate agreement for ganaxolone in Europe

CORRECTION: Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel

Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel

Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics

Penalty payment to a member of Orion’s Board of Directors for delay in notifying managers’ transaction

142,701 Orion Corporation A shares converted into B shares

3 Prominent Dividend Stocks For November 2024

Orion Research Foundation grants EUR 1,109,000 for research in 2025

Orion and Alligator Bioscience amend their agreement concerning two bispecific antibodies

Orion Corporation: Managers’ transactions – Henrik Stenqvist

Orion Group Interim Report January–September 2024

Inside information: Orion terminates ODM-111 development program due to narrow therapeutic window of the molecule

Orion publishes Interim Report for January–September 2024 and holds a webcast on 29 October 2024

Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU

Orion’s near-term climate targets approved by the Science Based Targets initiative

Orion OYJ (ORINY) Is a Great Choice for 'Trend' Investors, Here's Why

Orion’s collaboration partner Bayer submits application to U.S. FDA for third indication of darolutamide which has become the first ever Orion-originated blockbuster

Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation Collaboration in Oncology

Performance Overview